Table 1_The efficacy and safety of colistimethate sodium in the treatment of carbapenem-re

A prospective observational study in nine ICUs in Henan Province, China, from November 2021 to November 2023. It enrolled 222 patients aged 14 and over with culture-confirmed carbapenem-resistant Gram-negative bacilli infections to evaluate the clinical efficacy and safety of colistimethate sodium. The dataset was authored by Tingyuan Zhang and is available under a CC-BY-4.0 license.

Use Cases

• Modeling clinical response rates based on patient factors like APACHE II scores and infection site.
• Analyzing risk factors for acute kidney injury associated with colistimethate sodium treatment.
• Studying mortality predictors in ICU patients with polymicrobial or multi-site carbapenem-resistant infections.

Strengths

• Data is from a prospective, observational study design with a defined cohort of 222 patients.
• Reported clinical outcomes include specific rates: 82.5% clinical response, 19.8% 30-day mortality, and 20.4% incidence of acute kidney injury.
• Includes subgroup and multivariable regression analyses identifying independent risk factors for poor outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data table is unknown, which may limit suitability assessment.
• The dataset is very small at 12.3 KB, indicating limited scope or summary-level data.

Provenance

Source

figshare

Collection Method

Prospective observational study conducted in nine ICUs.

Time Range

November 2021 to November 2023

Freshness

Last updated 2026-05-29 04:45:29; freshness should be verified.

Geography

Henan Province, China